pmc logo imageJournal ListSearchpmc logo image
Logo of immunologyJournal URL: redirect3.cgi?&&auth=0paiSEVEmDzjSFlsr6uzhaEFL6PH79FxQPkBXBQ0h&reftype=publisher&artid=1385311&article-id=1385311&iid=128052&issue-id=128052&jid=337&journal-id=337&FROM=Article|Banner&TO=Publisher|Other|N%2FA&rendering-type=normal&&http://www.blackwell-synergy.com/loi/imm
Immunology. 1989 August; 67(4): 441–446.
PMCID: PMC1385311
Reversible injury of cultured rat oligodendrocytes by complement.
N J Scolding, W A Houston, B P Morgan, A K Campbell, and D A Compston
Section of Neurology, University of Wales College of Medicine, Heath Park, Cardiff.
Abstract
Rat oligodendrocytes are lysed on exposure to normal homologous serum as a result of classical pathway complement activation and attack in the absence of anti-myelin antibodies. The effect of non-lethal complement attack on oligodendrocytes in vitro was studied by exposing dissociated neonatal rat optic nerve cell cultures to low concentrations of complement alone and also in the presence of oligodendrocyte-specific monoclonal antibodies. Regardless of the mode of complement activation, non-lethal complement attack led to reversible cell injury, recovery following a transient rise in intracellular calcium and fall in ATP in the absence of membrane permeabilization to propidium iodide. A single episode of non-lethal injury had no effect on the ability of oligodendrocytes subsequently to express cell-specific antigens, but repeated episodes had a cumulative effect and ultimately resulted in cell death. Reversible and/or lytic complement-mediated oligodendrocyte injury has implications for the pathogenesis of human and experimental demyelinating diseases.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Images in this article
Click on the image to see a larger version.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Banik, NL; McAlhaney, WW; Hogan, EL. Calcium-stimulated proteolysis in myelin: evidence for a Ca2+-activated neutral proteinase associated with purified myelin of rat CNS. J Neurochem. 1985 Aug;45(2):581–588. [PubMed]
  • Berridge, MJ; Irvine, RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature. 312(5992):315–321. [PubMed]
  • Biesecker, G; Müller-Eberhard, HJ. The ninth component of human complement: purification and physicochemical characterization. J Immunol. 1980 Mar;124(3):1291–1296. [PubMed]
  • Blaurock, AE; Yale, JL. Calcium ions trigger the expansion in bistable myelin. Neurosci Lett. 1987 Jan 14;73(2):167–172. [PubMed]
  • Campbell, AK. Extraction, partial purification and properties of obelin, the calcium-activated luminescent protein from the hydroid Obelia geniculata. Biochem J. 1974 Nov;143(2):411–418. [PubMed]
  • Campbell, AK; Hallett, MB; Weeks, I. Chemiluminescence as an analytical tool in cell biology and medicine. Methods Biochem Anal. 1985;31:317–416. [PubMed]
  • Carney, DF; Hammer, CH; Shin, ML. Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+. J Immunol. 1986 Jul 1;137(1):263–270. [PubMed]
  • Compston, DA; Morgan, BP; Oleesky, D; Fifield, R; Campbell, AK. Cerebrospinal fluid C9 in demyelinating disease. Neurology. 1986 Nov;36(11):1503–1506. [PubMed]
  • DeLuca, M; McElroy, WD. Kinetics of the firefly luciferase catalyzed reactions. Biochemistry. 1974 Feb 26;13(5):921–925. [PubMed]
  • Einstein, ER; Csejtey, J; Dalal, KB; Adams, CW; Bayliss, OB; Hallpike, JF. Proteolytic activity and basic protein loss in and around multiple sclerosis plaques: combined biochemical and histochemical observations. J Neurochem. 1972 Mar;19(3):653–662. [PubMed]
  • Imagawa, DK; Osifchin, NE; Paznekas, WA; Shin, ML; Mayer, MM. Consequences of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives. Proc Natl Acad Sci U S A. 1983 Nov;80(21):6647–6651. [PubMed]
  • Linnington, C; Webb, M; Woodhams, PL. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol. 1984 6(6):387–396.Sep–Oct; [PubMed]
  • Ludwin, SK. Remyelination in the central nervous system and the peripheral nervous system. Adv Neurol. 1988;47:215–254. [PubMed]
  • Morgan, BP; Campbell, AK. The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem J. 1985 Oct 1;231(1):205–208. [PubMed]
  • Morgan, BP; Daniels, RH; Watts, MJ; Williams, BD. In vivo and in vitro evidence of cell recovery from complement attack in rheumatoid synovium. Clin Exp Immunol. 1988 Sep;73(3):467–472. [PubMed]
  • Morgan, BP; Dankert, JR; Esser, AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987 Jan 1;138(1):246–253. [PubMed]
  • Murray, N; Steck, AJ. Impulse conduction regulates myelin basic protein phosphorylation in rat optic nerve. J Neurochem. 1984 Jul;43(1):243–248. [PubMed]
  • Petrali, EH; Sulakhe, PV. Calcium ion stimulated protein kinases in myelin. Prog Brain Res. 1982;56:125–144. [PubMed]
  • Raff, MC; Miller, RH; Noble, M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature. 303(5916):390–396. [PubMed]
  • Ranscht, B; Clapshaw, PA; Price, J; Noble, M; Seifert, W. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactocerebroside. Proc Natl Acad Sci U S A. 1982 Apr;79(8):2709–2713. [PubMed]
  • Sanders, ME; Koski, CL; Robbins, D; Shin, ML; Frank, MM; Joiner, KA. Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. J Immunol. 1986 Jun 15;136(12):4456–4459. [PubMed]
  • Schlaepfer, WW. Vesicular disruption of myelin simulated by exposure of nerve to calcium ionophore. Nature. 1977 Feb 24;265(5596):734–736. [PubMed]
  • Scolding, NJ; Frith, S; Linington, C; Morgan, BP; Campbell, AK; Compston, DA. Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol. 1989 May;22(3):169–176. [PubMed]
  • Scolding, NJ; Morgan, BP; Houston, A; Campbell, AK; Linington, C; Compston, DA. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies. J Neurol Sci. 1989 Feb;89(2-3):289–300. [PubMed]
  • Seeger, W; Suttorp, N; Hellwig, A; Bhakdi, S. Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J Immunol. 1986 Aug 15;137(4):1286–1293. [PubMed]
  • Shirazi, Y; Imagawa, DK; Shin, ML. Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes. J Neurochem. 1987 Jan;48(1):271–278. [PubMed]
  • Sims, PJ; Wiedmer, T. Repolarization of the membrane potential of blood platelets after complement damage: evidence for a Ca++ -dependent exocytotic elimination of C5b-9 pores. Blood. 1986 Aug;68(2):556–561. [PubMed]
  • Smith, KJ; Hall, SM. Peripheral demyelination and remyelination initiated by the calcium-selective ionophore ionomycin: in vivo observations. J Neurol Sci. 1988 Jan;83(1):37–53. [PubMed]
  • Toews, AD; Fischer, HR; Goodrum, JF; Windes, S; Morell, P. Metabolism of phosphate and sulfate groups modifying the P0 protein of peripheral nervous system myelin. J Neurochem. 1987 Mar;48(3):883–887. [PubMed]
  • Vanguri, P; Shin, ML. Hydrolysis of myelin basic protein in human myelin by terminal complement complexes. J Biol Chem. 1988 May 25;263(15):7228–7234. [PubMed]